Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FWGE in Women With Ovarian Cancer
NCT02411565Phase 1Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Botanical Extract, Nutraceutical
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) comparing FWGE with Placebo (2 arms). Primary endpoint: Occurrence of Adverse Events Probably Related to Study Treatment up to 2 months. Started Mar 2016; status: terminated.
02
Drugs
fermented wheat germ extract
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02411565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411565.